The FDA has granted fast track designation to Pfizer for ervogastat in combination with clesacostat for treatment of patients with nonalcoholic steatohepatitis with liver fibrosis, according to a company press release.
Pfizer’s investigational combination therapy targets key enzymes for the regulation of lipid metabolism, diacylglycerol O-acyltransferase 2 and acetyl-CoA carboxylase. Inhibiting these enzymes has previously been shown to lower liver fat in patients with nonalcoholic fatty liver disease, a benefit that Pfizer believes could be leveraged to improve inflammation and